PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 EPAS ID: PAT8050695

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
CODIAK BIOSCIENCES, INC.	06/15/2023

RECEIVING PARTY DATA

Name:	LONZA SALES AG
Street Address:	MÜNCHENSTEINERSTRASSE 38
City:	BASEL
State/Country:	SWITZERLAND
Postal Code:	4052

PROPERTY NUMBERS Total: 218

Property Type	Number
Application Number:	62378122
Application Number:	16327282
Application Number:	62434985
Application Number:	62542697
Application Number:	16470180
Application Number:	17706281
Application Number:	62533629
Application Number:	16632122
Application Number:	62550543
Application Number:	62656956
Application Number:	16112547
Application Number:	16231012
Application Number:	16722884
Application Number:	18050005
Application Number:	62561206
Application Number:	62668217
Application Number:	16137176
Application Number:	18172176
Application Number:	62588143
Application Number:	16190058

PATENT REEL: 064251 FRAME: 0794

508003554

Property Type	Number
Application Number:	17014961
Application Number:	18045727
Application Number:	62587767
Application Number:	62634750
Application Number:	16765116
Application Number:	16194230
Application Number:	18057709
Application Number:	62611140
Application Number:	62723267
Application Number:	16236246
Application Number:	16921351
Application Number:	18049999
Application Number:	62629563
Application Number:	16969511
Application Number:	18052785
Application Number:	62647491
Application Number:	62680501
Application Number:	62688600
Application Number:	62756247
Application Number:	62822019
Application Number:	17040805
Application Number:	62688304
Application Number:	17254221
Application Number:	62750121
Application Number:	17288719
Application Number:	62800930
Application Number:	17428567
Application Number:	62801065
Application Number:	62801636
Application Number:	62851581
Application Number:	17428245
Application Number:	62822008
Application Number:	62835437
Application Number:	62840348
Application Number:	62891048
Application Number:	62901166
Application Number:	62946280
Application Number:	62984146

Property Type	Number
Application Number:	17441524
Application Number:	18050027
Application Number:	62822013
Application Number:	62835436
Application Number:	62903524
Application Number:	62946895
Application Number:	62984141
Application Number:	17593613
Application Number:	18050011
Application Number:	62822014
Application Number:	62835439
Application Number:	17441162
Application Number:	62835430
Application Number:	17293833
Application Number:	62835427
Application Number:	62840330
Application Number:	62851567
Application Number:	17594401
Application Number:	62851547
Application Number:	16881961
Application Number:	62891092
Application Number:	62903495
Application Number:	62962618
Application Number:	63035302
Application Number:	62870483
Application Number:	62886941
Application Number:	62895398
Application Number:	17634897
Application Number:	62886930
Application Number:	62900136
Application Number:	62936220
Application Number:	62944204
Application Number:	62989540
Application Number:	63023065
Application Number:	63035357
Application Number:	17635284
Application Number:	62886901
Application Number:	62900371

Property Type	Number
Application Number:	17635315
Application Number:	62886904
Application Number:	62900376
Application Number:	62886885
Application Number:	17635298
Application Number:	62886944
Application Number:	62900138
Application Number:	62903518
Application Number:	62936216
Application Number:	62989477
Application Number:	63035392
Application Number:	17635322
Application Number:	18050017
Application Number:	62870574
Application Number:	17271176
Application Number:	62906023
Application Number:	63059754
Application Number:	63066654
Application Number:	17754174
Application Number:	62906018
Application Number:	62906485
Application Number:	17763996
Application Number:	62906016
Application Number:	63066605
Application Number:	63070149
Application Number:	17763973
Application Number:	62906002
Application Number:	62989528
Application Number:	62704986
Application Number:	17754177
Application Number:	62905999
Application Number:	62931089
Application Number:	17774774
Application Number:	62962691
Application Number:	63047159
Application Number:	17793629
Application Number:	62962649
Application Number:	63035307

Property Type	Number
Application Number:	17624524
Application Number:	62989491
Application Number:	63010603
Application Number:	63016213
Application Number:	63035367
Application Number:	63050651
Application Number:	63055657
Application Number:	63059103
Application Number:	17906177
Application Number:	62989535
Application Number:	62704998
Application Number:	63154563
Application Number:	62989530
Application Number:	62704992
Application Number:	62989534
Application Number:	62704996
Application Number:	63001088
Application Number:	63003171
Application Number:	63006585
Application Number:	63017514
Application Number:	63142418
Application Number:	17906849
Application Number:	63035370
Application Number:	63161362
Application Number:	18000799
Application Number:	62992797
Application Number:	63023762
Application Number:	63035321
Application Number:	63035382
Application Number:	63066107
Application Number:	63028460
Application Number:	62704988
Application Number:	63181883
Application Number:	63035314
Application Number:	63035249
Application Number:	62704991
Application Number:	62704995
Application Number:	63066603

Property Type	Number
Application Number:	63069423
Application Number:	63131870
Application Number:	63136051
Application Number:	63145762
Application Number:	63166772
Application Number:	18042068
Application Number:	63082358
Application Number:	18246312
Application Number:	63082434
Application Number:	63083034
Application Number:	18246301
Application Number:	63082453
Application Number:	63161331
Application Number:	18246304
Application Number:	63088312
Application Number:	63141829
Application Number:	63160596
Application Number:	63169753
Application Number:	63225852
Application Number:	63244626
Application Number:	18248036
Application Number:	63082433
Application Number:	63150453
Application Number:	63150523
Application Number:	63150497
Application Number:	63169751
Application Number:	63255857
Application Number:	63261918
Application Number:	63364875
Application Number:	63357568
Application Number:	63371709
Application Number:	63357573
Application Number:	63385371
Application Number:	63369650
Application Number:	63371707
Application Number:	63371711
Application Number:	63357552
Application Number:	63390266

Property Type	Number
Application Number:	63490750
Application Number:	63499032
PCT Number:	US2022016828
PCT Number:	US2022016870
PCT Number:	US2022016825
PCT Number:	US2022023120
PCT Number:	US2022078150
PCT Number:	US2022077424

CORRESPONDENCE DATA

Fax Number: (703)712-8525

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent

using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: (703)712-8531

Email: mromanus@medlerferro.com, docketing@medlerferro.com

Correspondent Name: MEDLER FERRO WOODHOUSE & MILLS PLLC

Address Line 1: 8201 GREENSBORO DRIVE, SUITE 1060

Address Line 4: MCLEAN, VIRGINIA 22102

ATTORNEY DOCKET NUMBER:	0132-0000
NAME OF SUBMITTER:	JEFFREY K MILLS
SIGNATURE:	/Jeffrey K. Mills/
DATE SIGNED:	07/11/2023

Total Attachments: 55

source=Codiak - Lonza Patent Assignment Agreement#page1.tif
source=Codiak - Lonza Patent Assignment Agreement#page2.tif
source=Codiak - Lonza Patent Assignment Agreement#page3.tif
source=Codiak - Lonza Patent Assignment Agreement#page4.tif
source=Codiak - Lonza Patent Assignment Agreement#page5.tif
source=Codiak - Lonza Patent Assignment Agreement#page6.tif
source=Codiak - Lonza Patent Assignment Agreement#page7.tif
source=Codiak - Lonza Patent Assignment Agreement#page8.tif
source=Codiak - Lonza Patent Assignment Agreement#page9.tif
source=Codiak - Lonza Patent Assignment Agreement#page10.tif
source=Codiak - Lonza Patent Assignment Agreement#page11.tif
source=Codiak - Lonza Patent Assignment Agreement#page12.tif
source=Codiak - Lonza Patent Assignment Agreement#page13.tif
source=Codiak - Lonza Patent Assignment Agreement#page14.tif
source=Codiak - Lonza Patent Assignment Agreement#page15.tif
source=Codiak - Lonza Patent Assignment Agreement#page16.tif
source=Codiak - Lonza Patent Assignment Agreement#page17.tif
source=Codiak - Lonza Patent Assignment Agreement#page18.tif
source=Codiak - Lonza Patent Assignment Agreement#page19.tif
source=Codiak - Lonza Patent Assignment Agreement#page20.tif

source=Codiak - Lonza Patent Assignment Agreement#page21.tif
source=Codiak - Lonza Patent Assignment Agreement#page22.tif
source=Codiak - Lonza Patent Assignment Agreement#page23.tif
source=Codiak - Lonza Patent Assignment Agreement#page24.tif
source=Codiak - Lonza Patent Assignment Agreement#page25.tif
source=Codiak - Lonza Patent Assignment Agreement#page26.tif
source=Codiak - Lonza Patent Assignment Agreement#page27.tif
source=Codiak - Lonza Patent Assignment Agreement#page28.tif
source=Codiak - Lonza Patent Assignment Agreement#page29.tif
source=Codiak - Lonza Patent Assignment Agreement#page30.tif
source=Codiak - Lonza Patent Assignment Agreement#page31.tif
source=Codiak - Lonza Patent Assignment Agreement#page32.tif
source=Codiak - Lonza Patent Assignment Agreement#page33.tif
source=Codiak - Lonza Patent Assignment Agreement#page34.tif
source=Codiak - Lonza Patent Assignment Agreement#page35.tif
source=Codiak - Lonza Patent Assignment Agreement#page36.tif
source=Codiak - Lonza Patent Assignment Agreement#page37.tif
source=Codiak - Lonza Patent Assignment Agreement#page38.tif
source=Codiak - Lonza Patent Assignment Agreement#page39.tif
source=Codiak - Lonza Patent Assignment Agreement#page40.tif
source=Codiak - Lonza Patent Assignment Agreement#page41.tif
source=Codiak - Lonza Patent Assignment Agreement#page42.tif
source=Codiak - Lonza Patent Assignment Agreement#page43.tif
source=Codiak - Lonza Patent Assignment Agreement#page44.tif
source=Codiak - Lonza Patent Assignment Agreement#page45.tif
source=Codiak - Lonza Patent Assignment Agreement#page46.tif
source=Codiak - Lonza Patent Assignment Agreement#page47.tif
source=Codiak - Lonza Patent Assignment Agreement#page48.tif
source=Codiak - Lonza Patent Assignment Agreement#page49.tif
source=Codiak - Lonza Patent Assignment Agreement#page50.tif
source=Codiak - Lonza Patent Assignment Agreement#page51.tif
source=Codiak - Lonza Patent Assignment Agreement#page52.tif
source=Codiak - Lonza Patent Assignment Agreement#page53.tif
source=Codiak - Lonza Patent Assignment Agreement#page54.tif
source=Codiak - Lonza Patent Assignment Agreement#page55.tif

ASSIGNMENT OF U.S. AND NON-U.S. PATENT RIGHTS

THIS ASSIGNMENT OF U.S. AND NON-U.S. PATENT RIGHTS (this "<u>Assignment</u>"), made as of June 15, 2023, is entered into by and between Lonza Sales AG ("<u>Assignee</u>") and Codiak BioSciences, Inc. ("<u>Assignor</u>").

WHEREAS, Assignor and Assignee's affiliate, Lonza Houston, Inc. ("Buyer"), are party to that certain Asset Purchase Agreement, dated June 6, 2023 (the "Purchase Agreement"), pursuant to which Assignor agreed to sell, assign, transfer, convey, and deliver certain assets to Assignee, as designee of Buyer, including all of Assignor's right, title, and interest in and to the patents and patent applications identified on Schedule A hereto and the inventions captured in those patents and patent applications (the "Assigned Patents");

NOW THEREFORE, in consideration of the promises and the mutual covenants and agreements contained herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged by both Assignor and Assignee, Assignor and Assignee hereby agree as follows:

- 1. <u>Definitions</u>. Capitalized terms used but not defined herein shall have the meanings accorded to them in the Purchase Agreement.
- Assignment. Assignor hereby sells, conveys, assigns, delivers, and transfers to Assignee all of Assignor's right, title and interest in and to the Assigned Patents, including (i) any and all rights of priority thereto and renewals thereof; (ii) all patents and patent applications to which any of the Assigned Patents claim priority and all patents and patent applications claiming priority to any of the foregoing; and (iii) the right to sue and recover for past, present, and future infringements of the foregoing, and Assignee hereby accepts the foregoing sale, conveyance, assignment, delivery, and transfer from Assignor.
- 3. <u>Authority</u>. The officer that executes this Assignment on behalf of Assignor is authorized to bind and obligate each of the entities defined herein as part of Assignor and covenants that Assignor has not executed and will not execute an agreement in conflict with this Assignment. The officer that executes this Assignment on behalf of Assignee is authorized to bind and obligate the entity defined herein as Assignee.
- 4. <u>Recordation</u>. This Assignment has been executed and delivered by Assignor with the intention of recording it with the U.S. Patent and Trademark Office and also any non-U.S. patent and/or trademark offices.
- 5. <u>Further Assurances</u>. Both parties hereto covenant and agree to prepare, execute, acknowledge, and deliver to the other party hereto such other instruments, documents, and statements, and take such other action as may be reasonably requested in the discretion of the requesting party to carry out more effectively the purposes of this Assignment and to perfect the title to the Assigned Patents in Assignee, including, without limitation, the recordation by Assignee of this Assignment, or a suitable form hereof, in any patent and/or trademark office or other similar governmental authority, in each relevant jurisdiction throughout the world. Each party shall pay its own costs incurred to comply with such request.

- 6. <u>Purchase Agreement</u>. Nothing in this Assignment, express or implied, is intended to or shall be construed to supersede, modify, replace, amend, rescind, waive, expand, or limit in any way the rights of the parties under, or the terms of, the Purchase Agreement. To the extent that any provision of this Assignment conflicts or is inconsistent with the terms of the Purchase Agreement, the Purchase Agreement shall govern.
- 7. <u>Governing Law</u>. This Assignment shall be governed by, and construed in accordance with, the laws of the U.S. in respect of patent issues and in all other respects by the laws of the State of Delaware, without regard to its conflicts of laws rules.
- 8. <u>Counterparts</u>. This Assignment may be executed in one or more counterparts (including by facsimile or electronic .pdf submission), each of which shall be deemed to be an original and all of which shall be deemed to constitute the same agreement.

[Signature page follows]

2

IN WITNESS WHEREOF, Assignor and Assignee have executed this Assignment as of the date first written above.

ASSIGNOR

CODIAK BIOSCIENCES, INC.

Ву

Name: Paul Huygens

Title: Chief Restructuring Officer

REEL: 064251 FRAME: 0804

IN WITNESS WHEREOF, undersigned parties have caused this Agreement to be executed as of the date first written above.

ASSIGNEE

LONZA SALES AG

By

Name: Title:

 $\mathbf{B}\mathbf{y}$

Alchael Stanek Serioral Coursel Head Logal Teori Bassi

Name: Title:



SCHEDULE A ASSIGNED PATENTS

See attached.

Codiak Patents and Applications List

Codiak-Filed Applications

C0011US004	C0011US003	C0011US002	C0011US001	C0010WO001	C0010EP001	C0010US002	C0010US001	Ref#	I. Codial	· }
United States	United States	United States	United States	PCT	EPC	United States	United States	Country	< Patents and	j
Methods of measuring exosomes using intrinsic fluorescence.	Methods of suppressing delivery of exosomes to liver, lung, and spleen	Methods of suppressing delivery of exosomes to liver, lung, and spleen	Methods of suppressing delivery of exosomes to liver, lung, and spleen	Methods of suppressing delivery of exosomes to liver, lung, and spleen	Title	Codiak Patents and Applications List				
17/706,281	16/470,180	62/542,697	62/434,985	PCT/US2017 /047794	17844210.9	16/327,282	62/378,122	Application Number	Codiak-F	
03/28/2022	12/14/2017	08/08/2017	12/15/2016	08/21/2017	08/21/2017	08/21/2017	08/22/2016	Application Date	Codiak-Filed Applications	
2022-0326158-A1	2020-0025685			WO 2018/039119	3500244	2021-0290556		Publication Number	ations	
10/13/2022	01/23/2020			03/01/2018	06/26/2019	09/23/2021		Publication Date		
								Patent Number		
								Grant Date		
Pending	Abandoned	Expired	Expired	Expired	Pending	Pending L:		Status ENT FRA	ME: 080	7

PCT Methods of measuring PCT/152017 1214/2017 WO 2018/12154 0621/2018 Date Population of the reportion of the reportion Co.9533.629 07/17/2018 2020-0163998 05/28/2020 Pending PCT/152018 PCT/152018		C0014US004	C0014US003	C0014US002	C0014US001	C0013WO001	C0013EP001	C0013US002	C0013US001	C0011WO001	
Number Date Number Date Number Date Number Date Number Expired s using intrinsic enec. 70 finestarring search as using intrinsic PCT/US2017 12/14/2017 WO 2018/112154 06/21/2018 Expired Expired sucks produced from inflammatory inflammatory 16/632.122 07/17/2018 2020-0163998 05/28/2020 Abandon Abandon symal stromal cells inflammatory inflammatory inflammatory 18834409.7 02/17/2020 36/54995 05/27/2020 Abandon Abandon inflammatory inflammatory inflammatory Inflammatory Inflammatory Inflammatory Divided Pending inflammatory Inflammatory <th></th> <td>United States</td> <td>United States</td> <td>United States</td> <td>United States</td> <td>PCT</td> <td>EPC</td> <td>United States</td> <td>United States</td> <td>PCT</td> <td></td>		United States	United States	United States	United States	PCT	EPC	United States	United States	PCT	
Date Number Date Number Expired 12/14/2017 WO 2018/112154 06/21/2018 Expired 07/17/2017 Expired Expired 07/17/2018 2020-0163998 05/28/2020 Abandon 07/17/2018 2020-0163998 05/27/2020 Pending 02/17/2020 3654995 05/27/2020 Pending 07/17/2018 WO 2019/018349 01/24/2019 Expired 08/25/2017 Expired 04/12/2018 WO 2019/018349 01/24/2019 Expired 08/24/2018 2019-0060483 02/28/2019 10,195,290 02/05/2019 Issued 12/21/2018 2019-0117792 04/25/2019 10,561,740 02/18/2020 Issued		Preparation of therapeutic exosomes using membrane proteins	Nanovesicles produced from mesenchymal stromal cells for anti-inflammatory applications	Nanovesicles produced from mesenchymal stromal cells for anti-inflammatory applications	Nanovesicles produced from mesenchymal stromal cells for anti-inflammatory applications	Nanovesicles produced from mesenchymal stromal cells for anti-inflammatory applications	Methods of measuring exosomes using intrinsic fluorescence.				
Number Date Number Expired WO 2018/112154 06/21/2018 Expired 2020-0163998 05/28/2020 Expired 2020-0163998 05/28/2020 Abandon 3654995 05/27/2020 Pending WO 2019/018349 01/24/2019 Expired WO 2019/018349 01/24/2019 Expired 2019-0060483 02/28/2019 10,195,290 02/05/2019 Issued 2019-0117792 04/25/2019 10,561,740 02/18/2020 Issued		16/231,012	16/112,547	62/656,956	62/550,543	PCT/US2018 /042409	18834409.7	16/632,122	62/533,629	PCT/US2017 /066324	Number
Date Number Expired 154 06/21/2018 Expired 05/28/2020 Expired 05/28/2020 Abandom 05/27/2020 Pending 05/27/2020 Expired 249 01/24/2019 Expired 249 01/24/2019 Expired 349 01/24/2019 Issued	,	12/21/2018	08/24/2018	04/12/2018	08/25/2017	07/17/2018	02/17/2020	07/17/2018	07/17/2017	12/14/2017	Date
Expired Expi		2019-0117792	2019-0060483			WO 2019/018349	3654995	2020-0163998		WO 2018/112154	Number
Expired Expired Expired Abandon Abandon Expired Expired Expired Expired Expired Expired Expired		04/25/2019	02/28/2019			01/24/2019	05/27/2020	05/28/2020		06/21/2018	Date
Expired Expired Expired Expired Expired Expired Expired Expired Issued		10,561,740	10,195,290								Number
		02/18/2020	02/05/2019								
		Issued	Issued	Expired	Expired	Expired	Pending	Abandon			

C0014EP001	C0014EA001	C0014CO001	C0014CN001	C0014CL001	C0014CA001	C0014BR001	C0014AU001	C0014US006	C0014US005	Ref#
EPC	EURA	Colombia	China P.R.	Chile	Canada	Brazil	Australia	United States	United States	Country
Preparation of therapeutic exosomes using membrane proteins	Title									
18849251.6	202090474	NC2020/000 1872	2018800551 35.4	00428-2020	3,072,352	BR11202000 3354-5	2018321927	18/050,005	16/722,884	Application Number
08/24/2018	08/24/2018	08/24/2018	08/24/2018	08/24/2018	08/24/2018	08/24/2018	08/24/2018	10/26/2022	12/20/2019	Application Date
EP3672573A1		NC2020/0001872	CN111212632A	00428-2020	3072352A		2018321927A		2020-0222556	Publication Number
07/01/2020		06/19/2020	05/29/2020	11/27/2020	02/28/2019		02/27/2020		07/16/2020	Publication Date
										Patent Number
										Grant Date
Pending	Pending	Abandoned	Pending	Abandoned	Pending	Pending	Pending EEL: 06	Pending PATEN		Status

C00143G001	C0014PH001	C0014WO001	C0014NZ001	C0014MX001	C0014KR001	C0014JP001	C0014IN001	C0014IL001	C0014HK001	Ref#
Singapore	Philippines	PCT	New Zealand	Mexico	Republic of Korea	Japan	India	Israel	Hong Kong	Country
exosomes using membrane proteins	Preparation of therapeutic exosomes using membrane proteins	Title								
8R	1-2020-500308	PCT/US2018 /048026	761419	MX/A/2020/ 001790	10-2020- 7008265	2020-510532	2020170128 09	272786	6202002294 3.8	Application Number
00/24/2010	08/24/2018	08/24/2018	08/24/2018	08/24/2018	08/24/2018	08/24/2018	08/24/2018	08/24/2018	12/30/2020	Application Date
RA	201170201000	WO2019/040920			KR20200071065 A	2020-531018	202017012809	IL272786D0	40032715.	Publication Number
02/02/06/60	02/20/2020	02/28/2019			06/18/2020	11/05/2020	08/14/2020	04/30/2020	03/26/2021	Publication Date
										Patent Number
										Grant Date
rending	Pending	Expired	Pending	Status						
						R	EEL: 06	PATEN 64251 F		0810

C0015EP001	C0015US004	C0015US003	C0015US002	C0015US001	C0014ZA001	C0014UA001	C0014TH001	Ref#
Europe	United States	United States	United States	United States	South Africa	Ukraine	Thailand	Country
Production of extracellular vesicles in single-cell suspension using chemically defined cell culture media	Production of extracellular vesicles in single-cell suspension using chemically defined cell culture media	Production of extracellular vesicles in single-cell suspension using chemically defined cell culture media	Production of extracellular vesicles in single-cell suspension using chemically defined cell culture media	Production of extracellular vesicles in single-cell suspension using chemically defined cell culture media	Preparation of therapeutic exosomes using membrane proteins	Preparation of therapeutic exosomes using membrane proteins	Preparation of therapeutic exosomes using membrane proteins	Tide
18858922.0	18/172,176	16/137,176	62/668,217	62/561,206	2020/01103	A202001382	2001001021	Application Number
09/20/2018	02/21/2023	09/20/2018	05/07/2018	09/21/2017	08/24/2018	08/24/2018	08/24/2018	Application Date
3684381		2019-0085284						Publication Number
07/29/2020		03/21/2019						Publication Date
EP3684381								Patent Number
11/02/2022								Grant Date
Granted	Pending	Abandoned	Expired	Expired	Abandon REEL:	Pending PATE 064251		Status 0811

C0017US001	C0016US004	C0016US003	C0016US002	C0016US001	C0015EP011	C0015WO001	C0015HK001	Ref#
United States	United States	United States	United States	United States	Europe	PCT	Hong Kong	Country
Compositions of engineered exosomes and methods of loading luminal exosome payloads	Loading of extracellular vesicles through imparting of mechanical shear	Loading of extracellular vesicles through imparting of mechanical shear	Loading of extracellular vesicles through imparting of mechanical shear	Loading of extracellular vesicles through imparting of mechanical shear	Production of extracellular vesicles in single-cell suspension using chemically defined cell culture media	Production of extracellular vesicles in single-cell suspension using chemically defined cell culture media	Production of extracellular vesicles in single-cell suspension using chemically defined cell culture media	Title
62/587,767	18/045,727	17/014,961	16/190,058	62/588,143	22204880.3	PCT/US2018 /052074	18858922.0	Application Number
11/17/2017	10/11/2022	09/08/2020	11/13/2018	11/17/2017	11/01/2022	09/20/2018	01/14/2021	Application Date
		2021-0093568	2019-0175506			WO2019/060629	40034682	Publication Number
		04/01/2021	06/13/2019			03/28/2019	04/30/2021	Publication Date
								Patent 1
								Grant Date
Expired	Pending	Abandoned	Abandoned	Expired	Pending REEL REEL	Expired PATE : 064251 I		Status 0812

C0017CN002	C0017CA004	C0017AU004	C0017US005	C0017US004	C0017US003	C0017US002	Ref#
China P.R.	Canada	Australia	United States	United States	United States	United States	Country
Compositions of engineered exosomes and methods of loading luminal exosome payloads	Compositions of engineered exosomes and methods of loading luminal exosome payloads	Compositions of engineered exosomes and methods of loading luminal exosome payloads	Compositions of engineered exosomes and methods of loading luminal exosome payloads	Compositions of engineered exosomes and methods of loading luminal exosome payloads	Compositions of engineered exosomes and methods of loading luminal exosome payloads	Compositions of engineered exosomes and methods of loading luminal exosome payloads	Title
2018800722 50.2	3,082,588	2018367670	18/057,709	16/765,116	16/194,230	62/634,750	Application Number
11/16/2018	11/16/2018	11/16/2018	11/21/2022	11/16/2018	11/16/2018	02/23/2018	Application Date
CN111511384A	CA3082588A1	AU2018367670A 1		2020-0347112	2019-0151456		Publication Number
08/07/2020	05/23/2019	05/07/2020		11/05/2020	05/23/2019		Publication Date
							Patent Number
							Grant Date
Pending	Pending	Pending	Pending	Abandon: REE	Abandon: PAT L: 064251	Expired ENT FRAME:	Status 0813

Abandoned		05/28/2020	SG11202003871S A	11/16/2018	1120200387 1S	Compositions of engineered exosomes and methods of loading luminal exosome	Singapore	C0017SG001
Pending				11/16/2018	763681	Compositions of engineered exosomes and methods of loading luminal exosome payloads	New Zealand	C0017NZ001
Pending				11/16;/2018	MX/a/2020/0 04883	Compositions of engineered exosomes and methods of loading luminal exosome payloads	Mexico	C0017MX001
Pending		07/30/2020	KR20200091390 A	11/16/2018	10-2020- 7011470	Compositions of engineered exosomes and methods of loading luminal exosome payloads	Republic of Korea	C0017KR001
Pending		02/12/2021	2021-503300	11/16/2018	2020-545049	Compositions of engineered exosomes and methods of loading luminal exosome payloads	Japan	C0017JP004
Pending		06/30/2020	IL274634D0	11/16/2018	274634	Compositions of engineered exosomes and methods of loading luminal exosome payloads	Israel	C0017IL001
Pending		04/23/2021	40034409 A	01/29/2021	6202102449 0.6	Compositions of engineered exosomes and methods of loading luminal exosome payloads	Hong Kong	C0017HK001
Pending				11/16/2018	202090832	Compositions of engineered exosomes and methods of loading luminal exosome payloads	Eurasia	C0017EA004
Status	Number Grain Date	Date N	Number	Date	Number	THE	Country	ACL #

C0018CF001	C0018CA001	C0018BR001	C0018AU001	C0018US005	C0018US004	C0018US003	C0018US002	C0018US001	C0017WO001	Ref#
Chile	Canada	Brazil	Australia	United States	PCT	Country				
Exosomes for immune- oncology and anti- inflammatory therapy	Compositions of engineered exosomes and methods of loading luminal exosome payloads	Title								
01691-2020	3,085,471	BR11202001 3131-8	2018394238	18/049,999	16/921,351	16/236,246	62/723,267	62/611,140	PCT/US2018 /061679	Application Number
12/28/2018	12/28/2018	12/28/2018	12/28/2018	10/26/2022	07/06/2020	12/28/2018	08/27/2018	12/28/2017	11/16/2018	Application Date
1691-2020	CA3085471A1	BR112020013131 -8	AU2018394238A 1		2020-0407419	2019-0202892			WO2019/099942	Publication Number
11/13/2020	07/04/2019	12/08/2020	06/18/2020		12/31/2020	07/04/2019			05/23/2019	Publication Date
						10,723,782				Patent Number
						07/28/2020				Grant Date
Pending	Pending	Pending	Pending	Pending	Pending	Issued	Expired	Expired PATE	Expired NT	Status
						R	EEL: 0		RAME:	0815

	C0018MX001	C0018KR001	C0018JP001	C0018IN001	C0018IL001	C0018HK001	C0018EP001	C0018EA001	C0018CO001	C0018CN001	Ref#
	Mexico	Republic of Korea	Japan	India	Israel	НК	EP	Eurasia	Colombia	China	Country
	Exosomes for immune- oncology and anti- inflammatory therapy	Title									
	MX/a/2020/0 06672	10-2020- 7016594	2020-534610	2020170320 61	275600	6202102871 0.3	18895264.2	202091134	NC2020/000 9091	2018800833 35.0	Application Number
	12/28/2018	12/28/2018	12/28/2018	12/28/2018	12/28/2018	04/01/2021	12/28/2018	12/28/2018	12/28/2018	12/28/2018	Application Date
			2021-508691	202017032061 A	IL275600D0	40039260	3731849		NC2020/0009091	CN 111655271 A	Publication Number
			03/11/2021	09/18/2020	08/31/2020	07/09/2021	11/04/2020		12/21/2020	09/11/2020	Publication Date
											Patent Number
											Grant Date
	Pending	Pending PATEN	Pending JT	Status							
L							R	EEL: 06	4251 F		0816

C0019US003	C0019US002	C0019US001	C0018WO001	C0018ZA001	C0018UA001	C0018TH001	C0018SG001	C0018PH001	C0018NZ001	Ref#
United States	United States	United States	PCT	South Africa	Ukraine	Thailand	Singapore	Philippines	New Zealand	Country
Methods and compositions for macrophage polarization	Methods and compositions for macrophage polarization	Methods and compositions for macrophage polarization	Exosomes for immune- oncology and anti- inflammatory therapy	Title						
18/052,785	16/969,511	62/629,563	PCT/US2018 /068062	2020/03484	2020 03343	2001003284	1120200504 9Q	1-2020- 550805	765040	Application Number
11/04/2022	08/12/2020	02/12/2018	12/28/2018	12/28/2018	12/28/2018	12/28/2018	12/28/2018	12/28/2018	12/28/2018	Application Date
	2020-0407725		WO2019/133934							Publication Number
	12/31/2020		07/04/2019							Publication Date
	11,512,315 B2									Patent Number
	11/29/2022									Grant Date
Pending	Issued	Expired	Expired	Pending	Pending	Pending	Pending	Pending PATEN	Pending	Status
						R	EEL: 06	34251 F	RAME:	0817

C0019IL001	С0019НК001	C0019EP001	C0019EA001	C0019CO001	C0019CN001	C0019CL001	C0019CA001	C0019BR001	C0019AU001	Ref#
Israel	Hong Kong	Europe	Eurasia	Colombia	China	Chile	Canada	Brazil	Australia	Country
Methods and compositions for macrophage polarization	Title									
276409	6202103321 3.1	19710511.7	202091486	NC2020/000 9694	2019800110 11.0	02053-2020	3,088,009	BR11202001 6228-0	2019218991	Application Number
02/12/2019	02/12/2019	02/12/2019	02/12/2019	02/12/2019	02/12/2019	02/12/2019	02/12/2019	02/12/2019	02/12/2019	Application Date
	40043611	3752615		NC2020/0009694	CN 111918967 A		CA3088009A1			Publication Number
	09/17/2021	12/23/2020		10/30/2020	11/10/2020		08/15/2019			Publication Date
										Patent Number
										Grant Date
Pending	Pending	Pending	Pending	Abandoned	Pending	Pending	Pending	Pending PATEN	Pending T	Status
						R	EEL: 06	64251 F		0818

C0019UA001	C0019TW001	C0019TH001	C0019SG001	C0019PH001	C0019NZ001	C0019MX001	C0019KR001	C0019JP001	C0019IN001	Ref#
Ukraine	Taiwan	Thailand	Singapore	Philippines	New Zealand	Mexico	South Korea	Japan	India	Country
Methods and compositions for macrophage polarization	Title									
2020 04401	108104676	2001004404	1120200602 1S	1-2020- 551195	765669	MX/a/2020/0 08103	10-2020- 7022341	2020-542161	2020170385 29	Application Number
02/12/2019	02/12/2019	02/12/2019	02/12/2019	02/12/2019	02/12/2019	02/12/2019	02/12/2019	02/12/2019	02/12/2019	Application Date
	202003846		SG11202006021S A				KR20200120624 A	2021-512608	202017038529A	Publication Number
	01/16/2020		08/28/2020				10/21/2020	05/20/2021	10/02/2020	Publication Date
										Patent Number
										Grant Date
Pending	Status									
						R	EEL: 06	PATEN 84251 F		0819

	C0021CL001	C0021CA001	C0021BR001	C0021AU001	C0021AR001	C0021US006	C0021US005	C0021US004	C0021US003	C0021US002	C0021US001	C0019WO001	C0019ZA001	Ref#
	Chile	Canada	Brazil	Australia	Argentina	United States	PCT	South Africa	Country					
	Extracellular vesicle comprising STING-agonists	Exosome encapsulated STING-agonists	Methods and compositions for macrophage polarization	Methods and compositions for macrophage polarization	Title									
	02426-2020	3,093,849	BR11202001 90896	2019237508	P190100742	17/040,805	62/822,019	62/756,247	62/688,600	62/680,501	62/647,491	PCT/US2019 /017731	2020/04683	Application Number
	03/22/2019	03/22/2019	03/22/2019	03/22/2019	03/22/2019	09/23/2020	03/21/2019	11/06/2018	8102/22/90	06/04/2018	03/23/2018	02/12/2019	02/12/2019	Application Date
		CA3093849A1	BR112020019089 -6	AU2019237508A 1	AR 115013 A1	2021-0322327						WO2019/157535		Publication Number
		09/26/2019	12/29/2020	10/01/2020	11/18/2020	10/21/2021						08/15/2019		Publication Date
														Patent Number
														Grant Date
	Abandoned	Pending	Pending	Pending	Pending	Pending	Expired	Expired	Expired	Expired	Expired	Expired PATEN	Pending JT	Status
L										REE	L: 06	4251 F	RAME:	0820

/2020	202003032 01/16/2020	03/22/2019	108110166	Extracellular vesicle comprising STING-agonists	Taiwan	C0021TW001
		03/22/2019	2001005365	Extracellular vesicle comprising STING-agonists	Thailand	C0021TH001
10/29/2020	SG11202008636 1 YA	03/22/2019	1120200863 6Y	Extracellular vesicle comprising STING-agonists	Singapore	C0021SG001
		03/22/2019	1202055152 6	Extracellular vesicle comprising STING-agonists	Philippines	C0021PH001
		03/22/2019	767721	Extracellular vesicle comprising STING-agonists	New Zealand	C0021NZ001
		03/22/2019	MX/a/2020/0 09796	Extracellular vesicle comprising STING-agonists	Mexico	C0021MX001
		03/22/2019	10-2020- 7029390	Extracellular vesicle comprising STING-agonists	Korea	C0021KR001
08/02/2021	2021-518386	03/22/2019	2020-550606	Extracellular vesicle comprising STING-agonists	Japan	C0021JP001
10/01/2021	202017046059	03/22/2019	2020170460 59	Extracellular vesicle comprising STING-agonists	India	C0021IN001
		03/22/2019	277344	Extracellular vesicle comprising STING-agonists	Israel	C0021IL001
09/03/2021	40042867	03/22/2019	6202103316 3.8	Extracellular vesicle comprising STING-agonists	Hong Kong	C0021HK001
01/27/2021	3768310	03/22/2019	19719979.7	Extracellular vesicle comprising STING-agonists	Europe	C0021EP001
		03/22/2019	202091961	Extracellular vesicle comprising STING-agonists	Eurasia	C0021EA001
6 01/18/2021	NC2020/0013046	03/22/2019	NC2020/001 3046	Extracellular vesicle comprising STING-agonists	Colombia	C0021CO001
12/22/2020	CN 112118866A	03/22/2019	2019800203 20.4	Extracellular vesicle comprising STING-agonists	China	C0021CN001
Publication Date	Number	Date	Number	******	Country	ANCL TI

C0024US001	C0023HK001	C0023EP001	C0023WO001	C0023US002	C0023US001	C0021WO001	C0021ZA001	C0021UA001	Ref#
United States	Hong Kong	Europe	PCT	US	United States	PCT	South Africa	Ukraine	Country
Methods to improve potency of electroporation	Methods of measuring extracellular vesicles and nanoparticles in complex matrices by light scattering	Methods of measuring extracellular vesicles and nanoparticles in complex matrices by light scattering	Methods of measuring extracellular vesicles and nanoparticles in complex matrices by light scattering	Methods of measuring extracellular vesicles and nanoparticles in complex matrices by light scattering	Methods of measuring extracellular vesicles and nanoparticles in complex matrices by light scattering	Extracellular vesicle comprising STING-agonists	Extracellular vesicle comprising STING-agonists	Extracellular vesicle comprising STING-agonists	Title
62/750,121	6202104056 9.7	19739484.4	PCT/US2019 /038592	17/254,221	62/688,304	PCT/US2019 /023727	2020/05866	2020 05917	Application Number
10/24/2018	10/18/2021	12/15/2020	06/21/2019	12/18/2020	06/21/2018	03/22/20	03/22/2019	03/22/2019	Application Date
	40050976	3811054	WO2019/246591	2021-0262931		WO2019/183578			Publication Number
	12/31/2021	04/28/2021	12/26/2019	08/26/2021		09/26/2019			Publication Date
									Patent Number
									Grant Date
Expired	Pending	Pending	Expired	Pending	Expired	Expired A	Pending T	Pending	Status
					REEL: 06			ME:	0822

C0031US002	C0031US001	C0030WO001	C0030EP001	C0030US003	C0030US001	C0024EP001	C0024WO001 ¹	C0024US002	Ref#
United States	United States	PCT	Europe	United States	United States	Europe	PCT	United States	Country
Membrane protein scaffolds for exosome engineering	Membrane protein scaffolds for exosome engineering	Treatment of cancer metastasis by targeting exosome proteins	Treatment of cancer metastasis by targeting exosome proteins	Treatment of cancer metastasis by targeting exosome proteins	Treatment of cancer metastasis by targeting exosome proteins	Methods to improve potency of electroporation	Methods to improve potency of electroporation	Methods to improve potency of electroporation	Title
62/801,636	62/801,065	PCT/US2020 /016625	20709858.3	17/428,567	62/800,930	19804932.2	PCT/US2019 /057634	17/288,719	Application Number
02/05/2019	02/04/2019	02/04/2020	02/04/2020	08/04/2021	02/04/2019	10/23/2019	10/23/2019	04/26/2021	Application Date
		WO2020/163366	3920958	2022-0144942		3870700	WO2020/086701	2021-0395721	Publication Number
		08/13/2020	12/15/2021	05/12/2022		09/01/2021	04/30/2020	12/23/2021	Publication Date
									Patent Number
									Grant Date
Expired	Expired	Expired	Pending	Pending	Expired	Pending	Expired PATEN	Pending	Status
					R	EEL: 06			0823

¹ The family is also owned by MaxCyte, Inc.

C0031MX003	C0031KR003	C0031JP003	C0031IL003	C0031EP003	C0031EA003	C0031CA003	C0031AU003	C0031US004	C0031US003	Ref#
Mexico	Korea	Japan	Israel	Europe	Eurasia	Canada	Australia	United States	United States	Country
Membrane protein scatfolds for exosome engineering	Membrane protein scaffolds for exosome engineering	Title								
MX/a/2021/0 09337	10-2021- 7026834	2021-545391	285195	20714311.6	202192147	3,128,386	2020217716	17/428,245	62/851,581	Application Number
02/04/2020	02/04/2020	02/04/2020	02/04/2020	02/04/2020	02/04/2020	02/04/2020	02/04/2020	08/03/2021	05/22/2019	Application Date
		2022-519275		3921432				2022-0249373-A1		Publication Number
		03/22/2022		12/15/2021				08/11/2022		Publication Date
										Patent Number
										Grant Date
Pending	Expired	Status								
						R	EEL: 06	PATEN 64251 F		0824

C0032AU001	C0032AR001	C0032US009	C0032US008	C0032US007	C0032US006	C0032US005	C0032US004	C0032US003	C0032US002	C0032US001	C0031WO001	C0031SG003	C0031NZ003	Ref#
Australia	Argentina	United States	United States	PCT	Singapore	New Zealand	Country							
Extracellular Vesicles for vaccine delivery	Exosome for vaccine delivery	Membrane protein scaffolds for exosome engineering	Membrane protein scaffolds for exosome engineering	Membrane protein scaffolds for exosome engineering	Title									
2020240135	P200100821	18/050,027	17/441,524	62/984,146	62/946,280	62/901,166	62/891,048	62/840,348	62/835,437	62/822,008	PCT/US2020 /016629	1120210838 9Q	778560	Application Number
03/20/2020	03/25/2020	10/26/2022	09/21/2021	03/02/2020	12/10/2019	09/16/2019	08/23/2019	04/29/2019	04/17/2019	03/21/2019	02/04/2020	02/04/2020	02/04/2020	Application Date
	AR 118484 A1		2022-0168415								WO2020/163370			Publication Number
	10/06/2021		06/02/2022								08/13/2020			Publication Date
														Patent Number
														Grant Date
Pending	Pending	Pending	Pending	Expired	Expired	Expired	Expired	Expired	Expired	Expired	Expired	Pending	Pending	Status
										L R	EEL: 06	PATEN 34251 F		0825

	Pending					03/20/2020	1-2021- 552223	vaccine delivery Extracellular Vesicles for vaccine delivery	va Ex va	
	Pending Pending					03/20/2020	MX/a/2021/0 11241 780241	Extracellular Vesicles for vaccine delivery Extracellular Vesicles for	Extracellular Ve Extracellular Ve	Mexico Extracell vaccine of the vacc
	Pending					03/20/2020	10-2021- 7034252	Extracellular Vesicles for vaccine delivery	Extrac vaccin	Korea Extrac vaccin
	Pending			05/23/2022	2022-526127	03/20/2020	2021-556469	Extracellular Vesicles for vaccine delivery	Extra vacci	Japan Extra vacci
	Pending			02/11/2022	202117047355A	03/20/2020	2021170473 55	Extracellular Vesicles for vaccine delivery	Extra vacc	India Extra vacc
	Pending					03/20/2020	286556	Extracellular Vesicles for vaccine delivery	Extr vacc	Israel Extr
	Pending			09/09/2022	40067684	07/13/2022	6202205673 6.1	Extracellular Vesicles for vaccine delivery	Ext vac	Hong Kong Ext
	Pending			01/26/2022	EP3941937	03/20/2020	20721330.7	Extracellular Vesicles for vaccine delivery	Ext vac	Europe Ext
	Pending					03/20/2020	202192504	Extracellular Vesicles for vaccine delivery	Ext vac	Eurasia Ext
REE	Pending			01/17/2022	NC2021/0013895	03/20/2020	NC2021/001 3895	Extracellular Vesicles for vaccine delivery	Ex va	Colombia Ex
L: 06	Pending			02/22/2022	CN114080232A	03/20/2020	2020800373 88.6	Extracellular Vesicles for vaccine delivery	Ex va	China Ex
4251	Pending A					03/20/2020	02425-2021	Extracellular Vesicles for vaccine delivery	Ex vac	Chile Ex
FRA	Pending T					03/20/2020	3,133,311	Extracellular Vesicles for vaccine delivery	Ex	Canada Ex
ME:	Pending			11/30/2021	BR112021018694 -8	03/20/2020	BR11202101 8694-8	Extracellular Vesicles for vaccine delivery	Ex Vac	Brazil Ex
0826	Status	Grant Date	Patent Number	Publication Date	Publication Number	Application Date	Application Number	tle	Title	Country Ti

C0035EP001	C0035US007	C0035US006	C0035US005	C0035US004	C0035US003	C0035US002	C0035US001	C0032WO001	C0032ZA001	C0032TW001	C0032TH001	C0032SG001	Ref#
Europe	United States	PCT	South Africa	Taiwan	Thailand	Singapore	Country						
Process for preparing extracellular vesicles	Extracellular Vesicles for vaccine delivery	Title											
20720184.9	18/050,011	17/593,613	62/984,141	62/946,895	62/903,524	62/835,436	62/822,013	PCT/US2020 /024023	2021/06811	109109629	2101005627	1120210970 2Q	Application Number
03/20/2020	10/26/2022	09/21/2021	03/02/2020	12/11/2019	09/20/2019	04/17/2019	03/2/12/60	02/202/60	03/20/2020	0202/22/20	03/20/2020	03/20/2020	Application Date
EP3941607		2022-0387906-A1						WO2020/191361		202100164			Publication Number
01/26/2022		12/08/2022						09/24/2020		01/01/2021			Publication Date
													Patent 1 Number
													Grant Date
Pending	Pending	Pending	Expired	Expired	Expired	Expired	Expired	Expired	Pending	Abandon PAT	Pending ENT	Pending	Status 0827

C0037JP001	C0037IL001	C0037HK001	C0037EP001	C0037EA001	C0037CN001	C0037CA001	C0037AU001	C0035WO001	C0035HK001	Ref#
				A001					K 001	
Japan	Israel	Hong Kong	Europe	Eurasia	China	Canada	Australia	PCT	Hong Kong	Country
Extracellular vesicle conjugates and uses thereof	Process for preparing extracellular vesicles	Process for preparing extracellular vesicles	Tide							
2021-556470	286562	6202205673 4.6	20720186.4	202192490	2020800310 44.4	3,133,314	2020241903	PCT/US2020 /024038	6202205673 7.9	Application Number
03/20/2020	03/20/2020	07/13/2022	03/20/2020	03/20/2020	03/20/2020	03/20/2020	03/20/2020	03/20/2020	07/13/2022	Application Date
2022-525924		40067682	EP3941528		CN 11374925 A			WO2020/191369	62022056737.9	Publication Number
05/20/2022		09/09/2022	01/26/2022		12/03/2021			09/24/2020	09/09/2022	Publication Date
										Patent (
										Grant Date
Pending	Expired	Pending	Status							
						R	EEL: 06	PATEN 64251 F		0828

C0041AR001	C0041US002	C0041US001	C0037WO001	C0037US004	C0037US002	C0037US001	C0037SG001	C0037NZ001	C0037MX001	C0037KR001	Ref#
Argentina	United States	United States	PCT	United States	United States	United States	Singapore	New Zealand	Mexico	Korea	Country
Engineered extracellular vesicles and uses thereof	Engineered extracellular vesicles and uses thereof	Engineered extracellular vesicles and uses thereof	Extracellular vesicle conjugates and uses thereof	Title							
P190101375	17/293,833	62/835,430	PCT/US2020 /024057	17/441,162	62/835,439	62/822,014	1120210958 7T	780270	MX/a/2021/0 11242	10-2021- 7033075	Application Number
05/23/2019	05/13/2021	04/17/2019	03/20/2020	09/20/2021	04/17/2019	03/21/2019	03/20/2020	03/20/2020	03/20/2020	03/20/2020	Application Date
AR 115159 A1	2022-0017907		WO2020/191377								Publication Number
12/02/2020	01/20/2022		09/24/2020								Publication Date
											Patent Number
											Grant Date
Pending	Pending	Expired	Expired	Pending	Expired	Expired	Pending	Pending	Pending PATEN	Pending	Status
							R	EEL: 06	64251 F		0829

Pending					05/22/2019	MX/a/2021/0 05636	Engineered extracellular vesicles and uses thereof	Mexico	C0041MX001
					05/22/2019	10-2021- 7018358	Engineered extracellular vesicles and uses thereof	Korea	C0041KR001
			02/07/2022	2022-513049	05/22/2019	2021-526563	Engineered extracellular vesicles and uses thereof	Japan	C0041JP001
i			11/19/2021	202117026566	05/22/2019	2021170265 66	Engineered extracellular vesicles and uses thereof	India	C0041IN001
					05/22/2019	283167	Engineered extracellular vesicles and uses thereof	Israel	C0041IL001
	04/22/2022	HK400327 16	03/26/2021	40032716	12/30/2020	6202002294 4.6	Engineered extracellular vesicles and uses thereof	Hong Kong	C0041HK001
			09/21/2022	4059510	05/22/20219	21200884.1	Engineered extracellular vesicles and uses thereof	EPC	C0041EP002
	10/06/2021	3672614	07/01/2020	3672614 ²	05/22/2019	19731027.9	Engineered extracellular vesicles and uses thereof	EPC	C0041EP001
					05/22/2019	202191334	Engineered extracellular vesicles and uses thereof	Eurasia	C0041EA001
			08/20/2021	CN113286603A	05/22/2019	2019800833 66.0	Engineered extracellular vesicles and uses thereof	China	C0041CN001
					05/22/2019	01278-2021	Engineered extracellular vesicles and uses thereof	Chile	C0041CL001
					05/22/2019	3119720	Engineered extracellular vesicles and uses thereof	Canada	C0041CA001
			08/10/2021	BR112021009231 05	05/22/2019	BR11202100 9231-5	Engineered extracellular vesicles and uses thereof	Brazil	C0041BR001
					05/22/2019	2019378591	Engineered extracellular vesicles and uses thereof	Australia	C0041AU001
	Grant Date	Number	Date	Number	Date	Number	Title	Сопппу	Net #

² Validated in AL, AT, BA, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, KH, LT, LU, LV, MA, MC, MD, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TN, TR 24

6

C0057CA001	C0057BR001	C0057AU001	C0057US003	C0057US002	C0057US001	C0046WO001	C0046US001	C0045US005	C0045US004	C0045US003	C0045US002	Ref#
Canada	Brazil	Australia	United States	United States	United States	PCT	United States	United States	United States	United States	United States	Country
Extracellular vesicle linked to molecules and uses thereof	Extracellular vesicle linked to molecules and uses thereof	Extracellular vesicle linked to molecules and uses thereof	Extracellular vesicle linked to molecules and uses thereof	Extracellular vesicle linked to molecules and uses thereof	Extracellular vesicle linked to molecules and uses thereof	Method of inducing hematopoiesis	Method of inducing hematopoiesis	Extracellular vesicles targeting dendritic cells and uses thereof	Extracellular vesicles targeting dendritic cells and uses thereof	Extracellular vesicles targeting dendritic cells and uses thereof	Extracellular vesicles targeting dendritic cells and uses thereof	Title
3,145,924	BR11202200 2599-8	2020327360	17/634,897	62/895,398	62/886,941	PCT/US2020 /040746	62/870,483	63/035,302	62/962,618	62/903,495	62/891,092	Application Number
08/14/2020	08/14/2020	08/14/2020	02/11/2022	09/03/2019	08/14/2019	07/02/2020	07/03/2019	06/05/2020	01/17/2020	09/20/2019	08/23/2019	Application Date
	BR112022002599 -8		2022-0354963-A1			WO2021/003425						Publication Number
	07/19/2022		11/10/2022			01/07/2021						Publication Date
												Patent Number
												Grant Date
Pending	Pending	Pending	Pending	Expired	Expired	Expired	Expired	Expired	Expired	Expired PATEN	Expired	Status
								R	EEL: 06	64251 F		0832

C0057WO001	C0057ZA001	C0057SG001	C0057NZ001	C0057MX001	C0057KR001	C0057JP001	C0057IN001	C0057IL001	C0057HK001	C0057EP001	C0057EA001	C0057CN001	Ref#
PCT	South Africa	Singapore	New Zealand	Mexico	Korea	Japan	India	Israel	Hong Kong	Europe	Eurasia	China	Country
Extracellular vesicle linked to molecules and uses thereof	Extracellular vesicle linked to molecules and uses thereof	Extracellular vesicle linked to molecules and uses thereof	Extracellular vesicle linked to molecules and uses thereof	Extracellular vesicle linked to molecules and uses thereof	Extracellular vesicle linked to molecules and uses thereof	Extracellular vesicle linked to molecules and uses thereof	Extracellular vesicle linked to molecules and uses thereof	Extracellular vesicle linked to molecules and uses thereof	Extracellular vesicle linked to molecules and uses thereof	Extracellular vesicle linked to molecules and uses thereof	Extracellular vesicle linked to molecules and uses thereof	Extracellular vesicle linked to molecules and uses thereof	Title
PCT/US2020 /046560	2022/00951	1120220034 7Y	784386	MX/a/2022/0 01770	10-2022- 7008099	2022-508813	2022170073 70	290494	6202206592 0.0	20762006.3	202290481	2020800689 36.1	Application Number
08/14/2020	08/14/2019	08/14/2020	08/14/2020	08/14/2020	08/14/2020	08/14/2020	08/14/2020	08/14/2020	8/14/2020	08/14/2020	08/14/2020	08/14/2020	Application Date
WO2021/030777			784386			2022-550248			40078430	4013457		CN 114728078 A	Publication Number
02/18/2021			01/28/2022			12/01/2022			3/31/2023	6/22/2022		07/08/2022	Publication Date
													Patent Number
													Grant Date
Expired	Pending	Status											
									REEL		ATEN [*] 51 FR		0833

					3		ongonucieonaes		
Expired					09/13/2019	62/900,371	Extracellular vesicles with STAT3/NRas antisense	United States	C0060US002
Expired					08/14/2019	62/886,901	Extracellular vesicles with STAT3/NRas antisense oligonucleotides	United States	C0060US001
Expired			02/18/2021	WO2021/030780	08/14/2020	PCT/US2020 /046563	Extracellular vesicle-ASO constructs targeting CEBP/beta	PCT	C0058WO001
Abandoned					08/14/2020	2022/01845	Extracellular vesicle-ASO constructs targeting CEBP/beta	South Africa	C0058ZA001
Pending					08/14/2020	1120220113 8Q	Extracellular vesicle-ASO constructs targeting CEBP/beta	Singapore	C0058SG001
Pending					08/14/2020	785398	Extracellular vesicle-ASO constructs targeting CEBP/beta	New Zealand	C0058NZ001
Pending					08/14/2020	MX/a/2022/0 01769	Extracellular vesicle-ASO constructs targeting CEBP/beta	Mexico	C0058MX001
Pending					08/14/2020	10-2022- 7008102	Extracellular vesicle-ASO constructs targeting CEBP/beta	Korea	C0058KR001
Pending			10/17/2022	2022-544288	08/14/2020	2022-508815	Extracellular vesicle-ASO constructs targeting CEBP/beta	Japan	C0058JP001
Pending			07/01/2022	202217013717 A	08/14/2020	2022170137	Extracellular vesicle-ASO constructs targeting CEBP/beta	India	C0058IN001
Pending					08/14/2020	290497	Extracellular vesicle-ASO constructs targeting CEBP/beta	Israel	C0058IL001
Pending			01/17/2023	40076699	12/17/2022	6202206578 9.9	Extracellular vesicle-ASO constructs targeting CEBP/beta	Hong Kong	C0058HK001
Pending			06/22/2022	EP4013878	08/14/2020	20765127.4	Extracellular vesicle-ASO constructs targeting CEBP/beta	Europe	C0058EP001
t Grant Date Status er Grant Date Status	t)er	Patent Number	Publication Date	Publication Number	Application Date	Application Number	Title	Country	Ref#

C0062CN001	C0062CA001	C0062US002	C0062US001	C0061WO001	C0061US002	C0061US001	C0060WO001	C0060JP001	C0060EP001	C0060CN001	C0060CA001	C0060US003	Ref#
China	Canada	United States	United States	PCT	United States	United States	PCT	Japan	Europe	China	Canada	United States	Country
Extracellular vesicles with antisense oligonucleotides targeting KRas	Extracellular vesicles with antisense oligonucleotides	Extracellular vesicles with antisense oligonucleotides	Extracellular vesicles with antisense oligonucleotides	Extracellular vesicles with STAT3 antisense oligonucleotides	Title								
2020800707 52.9	3,147,701	17/635,298	62/886,885	PCT/US2020 /046550	62/900,376	62/886,904	PCT/US2020 /046549	2022-508816	20765124.1	2020800719 79.5	3,147,366	17/635,315	Application Number
08/14/2020	08/14/2020	02/14/2022	08/14/2019	08/14/2020	09/13/2019	08/14/2019	08/14/2020	08/14/2020	08/14/2020	08/14/2020	08/14/2020	02/14/2022	Application Date
CN114641570 A		2023-0018254-A1		WO2021/030769			WO2021/030768	2022-544934	EP4013875	CN 114729327 A			Publication Number
06/17/2022		01/19/2023		02/18/2021			02/18/2021	10/24/2022	06/22/2022	07/08/2022			Publication Date
													Patent Number
													Grant Date
Pending	Pending	Pending	Expired	Expired	Expired	Expired	Expired	Pending	Pending		Pending ATEN 51 FR		Status

C0063CN001	C0063CA001	C0063BR001	C0063AU001	C0063US008	C0063US007	C0063US006	C0063US005	C0063US004	C0063US003	C0063US002	C0063US001	C0062WO001	C0062JP001	C0062EP001	Ref#
China	Canada	Brazil	Australia	United States	PCT	Japan	Europe	Country							
Extracellular vesicle-ASO constructs targeting STAT6	Extracellular vesicles with antisense oligonucleotides targeting KRas	Extracellular vesicles with antisense oligonucleotides targeting KRas	Extracellular vesicles with antisense oligonucleotides targeting KRas	Title											
2020800687 92.X	3,147,680	BR11202200 2691-9	2020328611	18/050,017	17/635,322	63/035,392	62/989,477	62/936,216	815,806/29	62/900,138	62/886,944	PCT/US2020 /046564	2022-508819	20762007.1	Application Number
08/14/2020	08/14/2020	08/14/2020	08/14/2020	10/26/2022	08/14/2020	06/05/2020	03/13/2020	11/15/2019	09/20/2019	09/13/2019	08/14/2019	08/14/2020	08/14/2020	08/14/2020	Application Date
CN 114729356 A												WO2021/030781	2022-544290	EP4013872	Publication Number
07/08/2022												02/18/2021	10/17/2022	06/22/20222	Publication Date
															Patent Number
															Grant Date
Pending	Pending	Pending	Pending	Pending	Pending	Expired	Pending	Pending	Status						
										R	REEL		ATEN [*] 51 FR		0837

C0066US001	C0066EP002	C0063WO001	C0063ZA001	C0063SG001	C0063NZ001	C0063MX001	C0063KR001	C0063JP001	C0063IN001	C0063IL001	С0063НК001	C0063EP001	C0063EA001	Ref#
United States	Europe	PCT	South Africa	Singapore	New Zealand	Mexico	Korea	Japan	India	Israel	Hong Kong	Europe	Eurasia	Country
Extracellular vesicles targeting dendritic cells and uses thereof	Extracellular vesicles targeting dendritic cells and uses thereof	Extracellular vesicle-ASO constructs targeting STAT6	Title											
62/870,574	19765396.7	PCT/US2020 /046559	2022/01839	1120220125 9V	785083	MX/a/2022/0 01767	10-2022- 7008103	2022-508818	2022170133 81	290499	6202206579 0.7	20765126.6	202290518	Application Number
07/03/2019	08/23/2019	08/14/2020	08/14/2020	08/14/2020	08/14/2020	08/14/2020	08/14/2020	08/14/2020	08/14/2020	08/14/2020	12/17/2022	08/14/2020	08/14/2020	Application Date
	3841112	WO2021/030776						2022-544289	202217013381 A		40076700	EP4013877		Publication Number
	06/30/2021	02/18/2021						10/17/2022	07/01/2022		02/17/2023	06/22/2022		Publication Date
														Patent Number
														Grant Date
Expired	Pending	Expired	Pending	Status										
									REE	L: 06		ENT FR/	ME:	0838

States	C0069CN001 Ch	C0069CA001 Ca	C0069BR001 Br	C0069AU001 Au	C0068WO001 PCT	C0068US004 Un	C0068US003 Un	C0068US002 Un	C0068US001 Un	C0068IN001 India	C0068EP001 Eu	C0066TW001 Ta	C0066WO001 PCT	C0066US002 Un	Kel # Ca
Number N	China	Canada	Brazil	Australia		United States	United States	United States	United States		Europe	Taiwan		United States	Country
Application Publication Particular P	vesicle	vesicle	vesicle	Extracellular vesicle compositions	Methods of producing extracellular vesicles	Methods of producing extracellular vesicles	Methods of producing extracellular vesicles		Methods of producing extracellular vesicles	80	Methods of producing extracellular vesicles	Extracellular vesicles targeting dendritic cells and uses thereof	Extracellular vesicles targeting dendritic cells and uses thereof	Extracellular vesicles targeting dendritic cells and uses thereof	Tine
Number Date Number Crain Date Pending	2020800785 88.6	3,152,478	BR11202200 5614-1	2020355240	PCT/US2020 /052901	17/754,174	63/066,654	63/059,754	62/906,023	2022170215 30	20792799.7	108130488	PCT/US2019 /047937	17/271,176	Number
Pending Pend	09/25/2020	09/25/2020	09/25/2020	09/25/2020	09/25/2020	09/25/2020	08/17/2020	07/31/2020	09/25/2019	09/25/2020	09/25/2020	08/26/2019	08/23/2019	02/24/2021	Application Date
Number Pending Expired Pending Pending Pending Pending Pending	CN 114727947 A		BR112022005614 01 A2		WO2021/062290						EP4034276	202024120	WO2020/041720		Number
Pending Expired Expired Expired Expired Expired Expired Expired Expired Expired Pending Pending Pending Pending Pending Pending	07/08/2022		07/12/2022		04/01/2021					07/22/2022	08/03/2022	07/01/2020	02/27/2020		Publication Date
Pending															
															Grant Date
, , , , , , , , , , , , , , , , , , ,	Pending	Pending	Pending	Pending	Expired	Pending	Expired	Expired	Expired	Pending	Pending	l			Status

C0069WO001	C0069US003	C0069US002	C0069US001	C0069ZA001	C0069SG001	C0069NZ001	C0069MX001	C0069KR001	C0069JP001	C0069IN001	C0069IL001	С0069НК001	C0069EP001	C0069EA001	Ref#
PCT	United States	United States	United States	South Africa	Singapore	New Zealand	Mexico	Korea	Japan	India	Israel	Hong Kong	Europe	Eurasia	Country
Extracellular vesicle compositions	Title														
PCT/US2020 /52935	17/763,996	62/906,485	62/906,018	2022/03637	1120220303 7S	786737	MX/a/2022/0 03570	10-2022- 7013488	2022-518957	2022170230 76	291690	6202306764 8.3	20790126.5	202290970	Application Number
09/25/2020	0202/22/60	09/26/2019	09/25/2019	09/25/2020	0202/22/60	0202/22/60	0202/22/60	09/25/2020	09/25/2020	09/25/2020	09/25/2020	01/31/2023	09/25/2020	09/25/2020	Application Date
WO2021/062317									2022-549328	202217023076			EP4034081		Publication Number
04/01/2021									11/24/2022	07/29/2022			08/03/2022		Publication Date
															Patent Number
															Grant Date
Expired	Pending	Expired	Expired	Pending	Status										
										REE	L: 06		ENT FRA	ME:	0840

C0073EP001	C0072WO001	C0072US004	C0072US003	C0072US002	C0072US001	C0072KR001	C0072JP001	C0072EP001	C0072CA001	C0072AU001	Ref#
Europe	PCT	United States	United States	United States	United States	Korea	Japan	Europe	Canada	Australia	Country
Sting agonist comprising exosomes for treating	Sting agonist comprising exosomes combined with IL-12 displaying exosomes for treating a tumour	Sting agonist comprising exosomes combined with IL-12 displaying exosomes for treating a tumour	Combination therapy using extracellular vesicles	Combination therapy using extracellular vesicles	Combination therapy using extracellular vesicles	Sting agonist comprising exosomes combined with IL-12 displaying exosomes for treating a tumour	Sting agonist comprising exosomes combined with IL-12 displaying exosomes for treating a tumour	Sting agonist comprising exosomes combined with IL-12 displaying exosomes for treating a tumour	Sting agonist comprising exosomes combined with IL-12 displaying exosomes for treating a tumour	Sting agonist comprising exosomes combined with IL-12 displaying exosomes for treating a tumour	Title
20789765.3	PCT/US2020 /052587	17/763,973	63/070,149	63/066,605	62/906,016	10-2022- 7013485	2022-518958	20799859.2	3,152,488	2020351729	Application Number
09/24/2020	09/24/2020	09/24/2020	08/25/2020	08/17/2020	09/25/2019	09/24/2020	09/24/2020	09/24/2020	09/24/2020	09/25/2020	Application Date
EP4034247	WO/2021/062060	US-2022- 0395465-A1					2022-551420	EP4034150			Publication Number
08/03/2022	04/01/2021	12/15/2022					12/09/2022	08/03/2022			Publication Date
											Patent Number
											Grant Date
Pending	Expired	Pending	Expired	Expired	Expired	Pending	Pending	Pending	Pending PATE	Pending	Status
								REEL: 0		RAME:	0841

	C0080US001	C0080EP001	C0079WO001	C0079US002	C0079US001	C0076WO001	C0076US001	C0073WO001	C0073US004	C0073US003	C0073US002	C0073US001		Ref#
	United States	Europe	PCT	United States	United States	PCT	United States	PCT	United States	United States	United States	United States		Country
	Cholesterol assays for extracellular vesicles	Cholesterol assays for extracellular vesicles	High-throughput chromatography screening for extracellular vesicles	High-throughput chromatography screening for extracellular vesicles	High-throughput chromatography screening for extracellular vesicles	Exogenous loading of exosomes via lyophilization	Exogenous loading of exosomes via lyophilization	Sting agonist comprising exosomes for treating neuroimmunological disorders	Sting agonist comprising exosomes for treating neuroimmunological disorders	Method of treating neuroimmunological disorders	Method of treating neuroimmunological disorders	Method of treating neuroimmunological disorders	neuroimmunological disorders	Title
	62/962,691	21708407.8	PCT/US2020 /059135	17/774,774	62/931,089	PCT/US2020 /052583	62/905,999	PCT/US2020 /052584	17/754,177	62/704,986	62/989,528	62/906,002		Application Number
	01/17/2020	01/15/2021	11/05/2020	05/05/2022	11/05/2019	09/24/2020	09/25/2019	09/24/2020	09/24/2020	06/05/2020	03/13/2020	09/25/2019		Application Date
,		EP4090974	WO2021/092193	2022-0390437		WO2021/062057		WO2021/062058						Publication Number
		11/23/2022	05/14/2021	12/08/2022		04/01/2021		04/01/2021						Publication Date
														Patent Number
														Grant Date
	Expired	Pending	Expired	Pending	Expired	Expired	Expired	Expired	Pending	Expired	Expired	Expired		Status
									F	REEL:		TENT 1 FRA	ME:	0842

C0091US005	C0091US004	C0091US003	C0091US002	C0091US001	C0085WO001	C0085US003	C0085US002	C0085US001	C0085EP001	C0080WO001	C0080US003	C0080US002	Ref#
United States	United States	United States	United States	United States	PCT	United States	United States	United States	Europe	PCT	United States	United States	Country
Extracellular vesicles for treating neurological disorders	Exovacc for neurological disorders	Extracellular vesicles targeting t cells and uses thereof	Extracellular vesicles targeting t cells and uses thereof	Extracellular vesicles targeting t cells and uses thereof	Extracellular vesicles targeting t cells and uses thereof	Extracellular vesicles targeting t cells and uses thereof	Cholesterol assays for extracellular vesicles	Cholesterol assays for extracellular vesicles	Cholesterol assays for extracellular vesicles	Title			
63/050,651	63/035,367	63/016,213	63/010,603	62/989,491	PCT/US2020 /040773	17/624,524	63/035,307	62/962,649	20751829.1	PCT/US2021 /013722	17/793,629	63/047,159	Application Number
06/10/2020	06/05/2020	04/27/2020	03/15/2020	03/13/2020	07/02/2020	07/02/2020	06/05/2020	01/17/2020	07/02/2020	01/15/2021	01/15/2021	07/01/2020	Application Date
					WO2021/003445	2022-0251200-A1			EP3994158	WO2021/146616			Publication Number
					01/07/2021	8/11/2022			05/11/2022	07/22/2021			Publication Date
													Patent Number
													Grant Date
Expired	Expired	Expired	Expired	Expired	Expired	Pending	Expired	Expired	Pending	Expired	Pending	Expired	Status
								RE	EL: 06		ENT FRA	ME:	0843

C0095US002	C0095US001	C0094WO001	C0094US002	C0094US001	C0093US003	C0093US002	C0093US001	C0091EP001	C0091WO001	C0091US008	C0091US007	C0091US006	Ref#
United States	United States	PCT	United States	United States	United States	United States	United States	Europe	PCT	United States	United States	United States	Country
Extracellular vesicle targeting PMP22	Extracellular vesicle targeting PMP22	Methods of treating neuroinflammation	Methods of treating neuroinflammation	Methods of treating neuroinflammation	Methods of targeting extracellular vesicles to the central nervous system	Methods of targeting extracellular vesicles to the central nervous system	Methods of targeting extracellular vesicles to the central nervous system	Extracellular vesicles for treating neurological disorders	Tide				
62/704,996	62/989,534	PCT/US2021 /022428	62/704,992	62/989,530	63/154,563	62/704,998	62/989,535	21722594.5	PCT/US2021 /022420	17/906,177	63/059,103	63/055,657	Application Number
06/05/2020	03/13/2020	03/15/2021	06/05/2020	03/13/2020	02/26/2021	06/05/2020	03/13/2020	10/13/2022	03/15/2021	03/15/2021	07/30/2020	07/23/2020	Application Date
		WO2021/184020						4117717	WO2021/184017				Publication Number
		09/16/2021						01/18/2023	09/16/2021				Publication Date
													Patent (Number
													Grant Date
Expired	Expired	Expired	Expired	Expired	Expired	Expired	Expired	Pending	Expired		Expired ATEN	Expired T AME:	Status

C0097WO001 ³	C0097US007	C0097US005	C0097US004	C0097US003	C0097US002	C0097US001	C0097JP001	C0097EP001	C0097CA001	C0097AU001	Ref #
PCT	United States	United States	United States	United States	United States	United States	Japan	Europe	Canada	Australia	Country
Extracellular vesicles for Coronavirus Therapy	Extracellular vesicles for Therapy	Extracellular vesicles for Coronavirus Therapy	Title Extracellular vesicle targeting PMP22								
PCT/US2021 /023485	17/906,849	63/142,418	63/017,514	63/006,585	63/003,171	63/001,008	2022-556038	21717740.1	3,171,623	2021236763	Application Number PCT/US2021 /022433
03/22/2021	09/20/2022	02/03/2021	04/29/2020	04/07/2020	03/31/2020	03/27/2020	3/22/2021	10/20/2022	09/13/2022	10/20/2022	Application Date 03/15/2021
WO2021/189047								EP4121450			Publication Number WO2021/184021
09/23/2021								01/25/2023			Publication Date 09/16/2021
											Patent Number
											Grant Date
Expired	Pending	Expired	Expired	Expired	Expired	Expired	Pending	Pending	Pending	Pending ATEN	Status Expired

63/035,314	ods of Targeting cellular Vesicles to	United States Extracellular Vesicle for Treating Lung Disease	United States Extracellular Vesicle for Treating Lung Disease	United States Extracellul Treating L1	United States VNAR Extrac	United States VI Ex	United States	United States	United States	PCT	United States	United States	United	Country
icellular Vesicles 63/035,314 prising Gene Editing	to	Extracellular Vesicle for Treating Lung Disease	Extracellular Vesicle Treating Lung Disease	Extracellul Treating Lı	VNAF Extrac	E _x ≤		· · · · · · · · · · · · · · · · · · ·	ates		States	States	United States	Ţ
			for e	Extracellular Vesicle for Treating Lung Disease	VNAR/Camelid Antibody Extracellular Vesicles	VNAR/Camelid Antibody Extracellular Vesicles	Multifunctional extracellular vesicles and uses thereof	Multifunctional extracellular vesicles and uses thereof	Multifunctional extracellular vesicles and uses thereof	Anti-Transferrin Extracellular Vesicles	Anti-Transferrin Extracellular Vesicles	Anti-Transferrin Extracellular Vesicles	Anti-Transferrin Extracellular Vesicles	Title
0	PCT/US2021 /033668	63/181,883	62/704,988	63/028,460	63/066,107	63/035,382	63/035,321	63/023,762	62/992,797	PCT/US2021 /036234	18/000,799	63/161,362	63/035,370	Application Number
06/05/2020	05/21/2021	04/29/2021	06/05/2020	05/21/2020	08/14/2020	06/05/2020	06/05/2020	05/12/2020	03/20/2020	06/07/2021	12/05/2022	03/15/2021	06/05/2020	Application Date
	WO2021/237100									WO2021/248133				Publication Number
	11/25/2021									12/09/2021				Publication Date
														Patent Number
														Grant Date
Expired	Expired	Expired	Expired	Expired	Expired	Expired	Expired	Expired	Expired	Expired	Pending	Expired	Expired	Status

CU116EP	C0116CA001	C0114WO001	C0114US007	C0114US006	C0114US005	C0114US004	C0114US003	C0114US002	C0114US001	C0114JP001	C0114EP001	C0107US001	C0106US001	C0105US001	Ref#
Europe	Canada	United States	Japan	Europe	United States	United States	United States	Country							
Process for Preparing Extracellular Vesicles	Process for Preparing Extracellular Vesicles	Methods of Treating Cancer	Extracellular Vesicles for Nucleotide Delivery	Extracellular Vesicles Comprising VEGF	Extracellular Vesicles Comprising Hyaluronidase	Title									
21/98866.6	3,193,107	PCT/US2021 /046358	18/042,068	63/166,772	63/145,762	63/136,051	63/131,870	63/069,423	63/066,603	2023-511932	21778596.3	62/704,995	62/704,991	63/035,249	Application Number
09/23/2021	09/23/2021	08/17/2021	02/17/2023	03/26/2021	02/04/2021	01/11/2021	12/30/2020	08/24/2020	08/17/2020	8/17/2021	08/17/2021	06/05/2020	06/05/2020	06/05/2020	Application Date
		WO 2022/040223 A1													Publication Number
		02/24/2022													Publication Date
															Patent Number
															Grant Date
Pending	Pending	Pending	Pending	Expired	Expired	Expired	Expired	Expired	Expired	Pending	Pending	Expired	Expired	Expired	Status
										REE	L: 06		ENT FRA	AME:	0847

C0120US001	C0119WO001	C0119US003	C0119US002	C0119US001	C0119EP	C0119CA001	C0118WO001	C0118US003	C0118US002	C0118US001	C0116WO001	C0116US002	C0116US001	Ref#
United States	PCT	United States	United States	United States	Europe	Canada	PCT	Unites States	United States	United States	PCT	United States	United States	Country
Extracellular Vesicle-ASO Constructs Targeting STAT6	Method of Producing Extracellular Vesicle-Based Vaccines	Process for Preparing Extracellular Vesicles	Title											
63/088,312	PCT/US2021 /051742	18/246,304	63/161,331	63/082,453	21795085.6	3,192,470	PCT/US2021 /051777	18/246,301	63/083,034	63/082,434	PCT/US2021 /051783	18/246,312	63/082,358	Application Number
10/06/2020	09/23/2021	09/23/2021	03/15/2021	09/23/2020	09/23/2021	09/23/2021	09/23/2021	09/23/2021	09/24/2020	09/23/2020	09/23/2021	09/23/2021	09/23/2020	Application Date
	WO2022/066898						WO2022/066928				WO2022/066934			Publication Number
	03/31/2022						03/31/2022				03/31/2022			Publication Date
														Patent Number
														Grant Date
Expired	Expired	Pending	Expired	Expired	Pending	Pending	Expired	Pending	Expired	Expired	Expired	Pending	Expired	Status
									REE	L: 06		ENT FRA	ME:	0848

	C0126US001	C0125WO001	C0125US001	C0124WO001	C0124US001	C0121WO001	C0121US001	C0120WO001	C0120US007	C0120US006	C0120US005	C0120US004	C0120US003	C0120US002	Ref#
	United States	PCT	United States	PCT	United States	PCT	United States	PCT	United States	United States	Country				
Extracellular Vesicles	Methods of Loading	Optimization of Linker Chemistry for Loading of Payloads to Exosomes	Optimization of Linker Chemistry for Loading of Payloads to Exosomes	Use of Extracellular Vesicle With NLRP3 ASO	Use of Extracellular Vesicle With NLRP3 ASO	Extracellular Vesicles Comprising KRAS Antigen and Uses Thereof	Extracellular Vesicles Comprising KRAS Antigen and Uses Thereof	Extracellular Vesicle-ASO Constructs Targeting STAT6	Extracellular Vesicle-ASO Constructs Targeting STAT6	Extracellular Vesicle-ASO Constructs Targeting STAT6	Extracellular Vesicle-ASO Constructs Targeting STAT6	Title			
	63/150,497	PCT/US2022 /016870	63/150,523	PCT/US2022 /016828	63/150,453	PCT/US2021 /051720	63/082,433	PCT/US2021 /053825	18/248,036	63/244,626	63/225,852	63/169,753	63/160,596	63/141,829	Application Number
	02/17/2021	02/17/2022	02/17/2021	02/17/2022	02/17/2021	09/23/2021	09/23/2020	10/06/2021	10/06/2021	09/15/2021	07/26/2021	04/01/2021	03/12/2021	01/28/2021	Application Date
		WO2022/178180 A1		WO2022/178149 A2		WO2022/066883		WO2022/076596							Publication Number
		08/25/2022		08/25/2022		03/31/2022		04/14/2022							Publication Date
															Patent Number
															Grant Date
	Expired	Pending	Expired	Pending	Expired	Expired	Expired	Expired	Pending	Expired	Expired	Expired PAT	Expired T	Expired	Status

Application Number Date PCT/US2022 02/17/2022 /016825 63/169.751 04/01/2021 pCT/US2022 04/01/2021 or 63/255,857 10/14/2021 or PCT/US2022 10/14/2021 63/261,918 09/30/2021 63/364,875 05/17/2022 p-CT/US202/ 09/30/2022 g- 63/357,568 06/30/2022 63/371,709 08/17/2022 63/385,371 11/29/2022 63/385,371 11/29/2022 63/371,707 08/17/2022								Somprome a procedural		
WOODIL PCT Methods of Loading Extracellular Vesicles Application Number Application Date WOODIL PCT Methods of Loading Extracellular Vesicles PCT/US2022 02/17/2022 WOODIL United States Extracellular Vesicle PCT/US2022 04/01/2021 WOODIL PCT Extracellular Vesicle PCT/US2022 04/01/2022 PCO01 PCT Extracellular Vesicle Compositions 0/23120 10/14/2021 PCO01 PCT Modified Producer Cells for PCT/US2022 10/14/2021 PCO01 PCT Extracellular vesicle Comprising Cholesterol Tagged Sting-Agonist 63/261,918 09/30/2021 DUS001 United States Extracellular vesicle Comprising Cholesterol Tagged Sting-Agonist 63/261,918 09/30/2021 DUS002 US Extracellular vesicle Comprising Cholesterol Tagged Sting-Agonist PCT/US202/ 09/30/2022 PCTO Extracellular vesicle Comprising Cholesterol Tagged Sting-Agonist PCT/US202/ 09/30/2022 PCTO Extracellular Vesicles Sing-Agonist 63/357,568 06/30/2022 PCTO Extracellular Vesicle Sing-Agonist 63/357,573	Pending					08/17/2022	63/371,707	Extracellular Vesicle Comprising a Biologically	United States)139US001
WOOD1 PCT Methods of Loading Extracellular Vesicles Application Number Application Date VUS001 United States Extracellular Vesicle Extracellular Vesicle Compositions 63/169.751 04/01/2022 VWO001 PCT Extracellular Vesicle Compositions PCT/US2022 04/01/2022 VWO001 PCT Extracellular Vesicle Compositions 0/23120 04/01/2022 VWO001 PCT Modified Producer Cells for Extosome Production PCT/US2022 04/01/2022 VWO001 PCT Modified Producer Cells for PCT/US2022 10/14/2021 Exosome Production //078150 078150 VWS Extracellular Vesicle Comprising Cholesterol Tagged Sting-Agonist PCT/US202/ 63/364,875 05/17/2022 VWS Extracellular Vesicle Comprising Cholesterol Tagged Sting-Agonist PCT/US202/ PCT/US202/ 09/30/2022 VWS Extracellular Vesicle Comprising Cholesterol Tagged Sting-Agonist PCT/US202/ 9/7424 9/7424 VWS Extracellular Vesicles Sting-Agonist PCT/US202/ 9/30/2022 9/30/2022 VWS Extracellular Vesicle Comprising Cholesterol Agonist PCT/WWS 9/30/2022 9	Pending					07/27/2022	63/369,650	Extracellular Vesicle-ASO Constructs Targeting CEBP/BETA	United States	C0138US001
KOO001 PCT Methods of Loading Extracellular Vesicles Application Date VIS001 United States Extracellular Vesicle 63/169.751 04/01/2022 VWO001 PCT Extracellular Vesicle Compositions PCT/US2022 04/01/2021 VWO001 PCT Extracellular Vesicle Compositions PCT/US2022 04/01/2022 VWO001 United States Modified Producer Cells for Cells for PCT/US2022 10/14/2021 PCO01 PCT Modified Producer Cells for PCT/US2022 10/14/2021 PCO01 PCT Modified Producer Cells for PCT/US2022 10/14/2021 Extracellular vesicle Comprising Cholesterol Tagged Sting-Agonist 63/261.918 09/30/2021 DUS001 United States Extracellular vesicle Comprising Cholesterol Tagged Sting-Agonist 63/364.875 05/17/2022 DYS002 PCT Extracellular vesicle Comprising Cholesterol Tagged Sting-Agonist 63/364.875 05/17/2022 DYS001 United States Extracellular Vesicle Sting-Agonist 63/357.568 06/30/2022 DYS001 United States Extracellular Vesicle Sting-Agonist 63/357.578 <t< td=""><td>Pending</td><th></th><td></td><td></td><td></td><td>11/29/2022</td><td>63/385,371</td><td>Exo-Aso Stat6 Dosing</td><td>United States</td><td>C0137US002</td></t<>	Pending					11/29/2022	63/385,371	Exo-Aso Stat6 Dosing	United States	C0137US002
SWOO01 PCT Methods of Loading Extracellular Vesicles PCT/US2022 O2/17/2022 7US001 United States Extracellular Vesicle 63/169,751 04/01/2021 WO001 PCT Extracellular Vesicle 63/169,751 04/01/2021 WO001 PCT Extracellular Vesicle PCT/US2022 04/01/2022 WO001 PCT Extracellular Vesicle PCT/US2022 04/01/2022 DUS001 United States Modified Producer Cells for Exosome Production PCT/US2022 10/14/2021 DUS001 PCT Extracellular vesicle 63/251,918 09/30/2021 DUS002 US Extracellular vesicle 63/261,918 09/30/2021 DUS002 US Extracellular vesicle 63/364,875 05/17/2022 DUS002 US Extracellular vesicle 63/364,875 05/17/2022 DUS002 PCT Extracellular vesicle 63/364,875 05/17/2022 DUS003 PCT Extracellular vesicle 63/364,875 05/17/2022 DUS004 PCT Extracellul	Pending					06/30/2022	63/357,573	Exo-Aso Stat6 Dosing	United States	C0137US001
WOO01 PCT Methods of Loading Extracellular Vesicles PCT/US2022 02/17/2022 7US001 United States Extracellular Vesicle 63/169,751 04/01/2021 7US001 PCT Extracellular Vesicle PCT/US2022 04/01/2021 7US001 United States Modified Producer Cells for Exosome Production /023120 10/14/2021 PPC001 PCT Modified Producer Cells for Exosome Production 63/255,857 10/14/2021 PPC001 PCT Modified Producer Cells for Exosome Production PCT/US2022 10/14/2022 PPC001 PCT Extracellular vesicle Comprising Cholesterol Tagged Sting-Agonist 63/261,918 09/30/2021 DUS002 US Extracellular vesicle Comprising Cholesterol Tagged Sting-Agonist 63/364,875 05/17/2022 PPC001 PCT Extracellular vesicle Comprising Cholesterol Tagged Sting-Agonist Extracellular vesicle Comprising Cholesterol Comprising Cholesterol PCT/US202 09/30/2022 PPC001 PCT Extracellular vesicle Comprising Cholesterol Com	Pending					08/17/2022	63/371,709	Extracellular Vesicle Comprising a Biologically Active Molecule and a Cleavable Linker	United States	C0134US001
KOOO01 PCT Methods of Loading Extracellular Vesicles Application Number (Number) Application Date 7US001 United States Extracellular Vesicles 63/169,751 04/01/2022 7WO001 PCT Extracellular Vesicle Compositions PCT/US2022 04/01/2021 9US001 United States Modified Producer Cells for Exosome Production 63/255,857 10/14/2022 9PC001 PCT Modified Producer Cells for Exosome Production PCT/US2022 10/14/2021 9PC001 PCT Modified Producer Cells for Exosome Production 9CT/US2022 10/14/2022 9PC001 PCT Extracellular vesicle Comprising Cholesterol 63/261,918 09/30/2021 9PC001 United States Extracellular vesicle Comprising Cholesterol 63/364,875 05/17/2022 9PC001 PCT Extracellular vesicle Comprising Cholesterol 63/364,875 05/17/2022 10PC001 PCT Extracellular vesicle Comprising Cholesterol 63/364,875 05/17/2022 10PC001 PCT Extracellular Vesicle Comprising Cholesterol 63/364,875 05/17/2022	Pending					06/30/2022	63/357,568	Extracellular Vesicles Sting- Agonist	United States	C0133US001
KountryTitleApplication NumberApplication Date5WO001PCTMethods of Loading Extracellular VesiclesPCT/US202202/17/20227US001United StatesExtracellular Vesicle Compositions63/169,75104/01/20217WO001PCTExtracellular Vesicle CompositionsPCT/US202204/01/20219US001United StatesModified Producer Cells for Exosome Production63/255,85710/14/20219PC001PCTModified Producer Cells for Exosome ProductionPCT/US202210/14/20219US001United StatesExtracellular vesicle Comprising Cholesterol Tagged Sting-Agonist63/261,91809/30/20219US002USExtracellular vesicle Comprising Cholesterol Tagged Sting-Agonist63/364,87505/17/2022	56468 04/06/2023 Pending	04/06/2023)56468	WO2023/056468	09/30/2022	PCT/US202/ 077424	Extracellular vesicle Comprising Cholesterol Tagged Sting-Agonist	PCT	C0130PC001
CountryTitleApplication NumberApplication NumberApplication DateWO001PCTMethods of Loading Extracellular VesiclesPCT/US2022 /01682502/17/20227US001United StatesExtracellular Vesicle Compositions63/169,751 	Pending					05/17/2022	63/364,875	Extracellular vesicle Comprising Cholesterol Tagged Sting-Agonist	US	C0130US002
SWO001PCTMethods of Loading Extracellular VesiclesPCT/US2022 /016825PCT/US2022 /016825O2/17/20227WO001United StatesExtracellular Vesicle Compositions63/169,751 /02312004/01/20217WO001PCTExtracellular Vesicle CompositionsPCT/US2022 /02312004/01/20219US001United States Exosome ProductionPCT/US2022 /02312004/01/2022 /0231209PC001PCTModified Producer Cells for Exosome Production63/255,857 /07815010/14/2021 /078150	Expired					09/30/2021	63/261,918	Extracellular vesicle Comprising Cholesterol Tagged Sting-Agonist	United States	C0130US001
CountryTitleApplication NumberApplication Date5WO001PCTMethods of Loading Extracellular VesiclesPCT/US2022 02/17/2022 02/17/20227US001United StatesExtracellular Vesicle Compositions63/169,751 04/01/20217WO001PCTExtracellular Vesicle CompositionsPCT/US2022 04/01/2022 04/01/20229US001United StatesModified Producer Cells for Exosome Production63/255,857 10/14/2021	Pending					10/14/2022	PCT/US2022 /078150	Modified Producer Cells for Exosome Production	PCT	C0129PC001
CountryTitleApplication NumberApplication Date5WO001PCTMethods of Loading Extracellular VesiclesPCT/US202202/17/20227US001United StatesExtracellular Vesicle63/169,75104/01/2021CompositionsExtracellular VesiclePCT/US202204/01/20217WO001PCTExtracellular VesiclePCT/US202204/01/2022	Expired					10/14/2021	63/255,857	Modified Producer Cells for Exosome Production	United States	C0129US001
CountryTitleApplication NumberApplication Date5WO001PCTMethods of Loading Extracellular VesiclesPCT/US202202/17/20227US001United StatesExtracellular Vesicle63/169,75104/01/2021	/212884 10/6/2022 Pending	10/6/2022		12884	WO2022/2	04/01/2022	PCT/US2022 /023120	Extracellular Vesicle Compositions	PCT	C0127WO001
CountryTitleApplication NumberApplication Date5WO001PCTMethods of Loading Extracellular VesiclesPCT/US202202/17/2022	Expired ENT					04/01/2021	63/169,751	Extracellular Vesicle Compositions	United States	C0127US001
Country Title Application Application Number Date	178147 08/25/2022 Pending	08/25/2022		 178147	WO2022/178147	02/17/2022	PCT/US2022 /016825	Methods of Loading Extracellular Vesicles	PCT	C0126WO001
	n Publication Patent Grant Date Status Date Number Grant Date	Publication Patent Grant Date Number	Publication Date	n	Publication Number	Application Date	Application Number	Title	Country	Ref#

C0149US001	C0148US001	C0142US001	C0141US001	C0140US001		Ref#
United States	United States	United States	United States	United States		Country
Process for Preparing Extracellular Vesicles	Methods of Producing Extracellular Vesicle	Use of Monolithic Anion Exchange Chromatography and Light Scattering for Quantifying Extracellular Vesicles	Methods of Treating a Tumor	Extracellular Vesicle Comprising a Biologically Active Molecule and a Cell Penetrating Peptide Cleavable Linker	Active Molecule and a Dual Cleavable Linker	Title
63/499,032	63/490,750	63/390,266	63/357,552	63/371,711		Application Number
04/28/2023	03/16/2023	07/19/2022	06/30/2022	08/17/2022		Application Date
						Publication Number
						Publication Date
						Patent Number
						Grant Date
Pending	Pending	Pending RFF	Pending 06	Pending Pending PATENT 64251 FRA	ME.	Status 0.851

For: Codiak BioSciences

Updated: June 11, 2023

Acquired Families - Currently Codiak BioSciences, Inc.

II.

Ref#	Country	Title	Application Number	Application Date	Publication Number	Publication Date	Patent Number	Grant Date	Status
C0004US001	United States	Exosome transfer of nucleic acids to cells	60/797,149	05/03/2006					Expired FN
C0004US002	United States	Exosome transfer of nucleic acids to cells	11/799,148	04/30/2007	2007-0298118	12/27/2007	9,085,778	07/21/2015	Abandoned PA
C0004US003	United States	Exosome transfer of nucleic acids to cells	14/750,457	06/25/2015	2015-0290343	10/15/2015	9,629,929	04/25/2017	Issued
C0004US004	United States	Exosome transfer of nucleic acids to cells	15/476,844	03/31/2017	2017-0258938	09/14/2017	9,889,210	02/13/2018	Issued
C0004US005	United States	Exosome transfer of nucleic acids to cells	15/857,539	12/28/2017	2018-0236104	08/23/2018			Abandoned
C0004US006	United States	Exosome transfer of nucleic acids to cells	16/201,937	11/27/2018	2019-0111155	04/18/2019	10,695,443	06/30/2020	Issued
C0004US007	United States	Exosome transfer of nucleic acids to cells	16/905,719	06/18/2020	2021-0000976	01/07/2021			Pending
С0004СН001	Switzerland	Exosome transfer of nucleic acids to cells	07748459.0	05/02/2007	2010663	01/07/2009	2010663	03/18/2015	Abandoned
C0004CN001	China P.R.	Exosome transfer of nucleic acids to cells	2007800154 69	05/02/2007	101432432	05/13/2009			Abandoned
C0004CN002	China P.R.	Exosome transfer of nucleic acids to cells							Abandoned
C0004CN003	China P.R.	Exosome transfer of nucleic acids to cells	2015110229 04.5	05/02/2007	105838739	08/10/2016			Abandoned
C0004CN004	China P.R.	Exosome transfer of nucleic acids to cells	2015110278 01.8	05/02/2007	105886535	08/24/2016			Abandoned
C0004CN005	China P.R.	Exosome transfer of nucleic acids to cells	2015110206 35.9	05/02/2007	105821081	08/03/2016			Abandoned
C0004DE001	Germany	Exosome transfer of nucleic acids to cells	2010663	05/02/2007	2010663	01/07/2009	602007040 676.5	03/18/2015	Abandoned

Ref#	Country	Title	Application Number	Application Date	Publication Number	Publication Date	Patent Number	Grant Date	Status
C0004EP001	EPC	Exosome transfer of nucleic acids to cells	07748459.0	05/02/2007	2010663	01/07/2009	2010663	03/18/2015	Abandoned
C0004EP002	EPC	Exosome transfer of nucleic acids to cells	15158949.6	05/02/2007	2905339	08/12/2015			Abandoned X
C0004EP003	EPC	Exosome transfer of nucleic acids to cells	18158203.2	05/02/2007	3378942	09/26/2018			Abandoned P
C0004ES001	Spain	Exosome transfer of nucleic acids to cells	07748459.0	05/02/2007	2010663	01/07/2009	2539760	03/18/2015	Abandoned
C0004FR001	France	Exosome transfer of nucleic acids to cells	07748459.0	05/02/2007	2010663	01/07/2009	2010663	03/18/2015	Abandoned
C0004GB001	United Kingdom	Exosome transfer of nucleic acids to cells	07748459.0	05/02/2007	2010663	01/07/2009	2010663	03/18/2015	Abandoned
С0004НК003	Hong Kong	Exosome transfer of nucleic acids to cells	19120924.6	03/14/2019					Abandoned
C0004IE001	Ireland	Exosome transfer of nucleic acids to cells	07748459.0	05/02/2007	2010663	01/07/2009	2010663	03/18/2015	Abandoned
C0004IT001	Italy	Exosome transfer of nucleic acids to cells	5020150000 24792	05/02/2007	2010663	01/07/2009	2010663	03/18/2015	Abandoned
C0004WO001	PCT	Exosome transfer of nucleic acids to cells	PCT/SE2007 /050298	05/02/2007	WO 2007/126386	11/08/2007			Expired
C0005US001	United States	Delivery of therapeutic agent	14/442,578	11/13/2013	2016-0168572	06/16/2016	9,856,477	01/02/2018	Abandoned
C0005US002	United States	Delivery of therapeutic agent	15/824,793	11/28/2017	2018-0135056	05/17/2018	10,370,663	08/06/2019	Issued
C0005US003	United States	Delivery of therapeutic agent	16/530,750	08/02/2019	2020-0063138	02/27/2020			Abandoned
C0005CA001	Canada	Delivery of therapeutic agent	2,930,339	11/13/2013	2,930,339	05/22/2014			Abandoned
C0005CH001	Switzerland	Delivery of therapeutic agent	13789802.9	11/13/2013	2920306	09/23/2015	2920306	06/27/2018	Abandoned

Ref#	Country	Title	Application Number	Application Date	Publication Number	Publication Date	Patent Number	Grant Date	Status
C0005CN001	China P.R.	Delivery of therapeutic agent	2013800696 83.X	11/13/2013	CN105051192A	11/11/2015	ZL2013 8 0069683.X	04/17/2020	Abandoned
C0005DE001	Germany	Delivery of therapeutic agent	2920306	11/13/2013	2920306	09/23/2015	60 2013 039 472.5	06/27/2018	Abandoned X
C0005EP001	EPC	Delivery of therapeutic agent	13789802.9	11/13/2013	2920306	09/23/2015	2920306	06/27/2018	Abandoned P
C0005EP002	EPC	Delivery of therapeutic agent	18172402.2	11/13/2013	3415627	12/19/2018			Abandoned
C0005ES001	Spain	Delivery of therapeutic agent	2920306	11/13/2013	2920306	09/23/2015	ES2686129 (T3)	06/27/2018	Abandoned
C0005FR001	France	Delivery of therapeutic agent	13789802.9	11/13/2013	2920306	09/23/2015	2920306	06/27/2018	Abandoned
C0005GB001	United Kingdom	Delivery of therapeutic agent	13789802.9	11/13/2013	2920306	09/23/2015	2920306	06/27/2018	Abandoned
С0005НК001	Hong Kong	Delivery of therapeutic agent	16103132.5	03/17/2016	1216105 A	10/14/2016	1216105 B	02/01/2019	Abandoned
С0005НК002	Hong Kong	Delivery of therapeutic agent	19100801.8	01/28/2019					Abandoned
C0005IE001	Ireland	Delivery of therapeutic agent	13789802.9	11/13/2013	2920306	09/23/2015	2920306	06/27/2018	Abandoned
C0005IT001	Italy	Delivery of therapeutic agent	5020180000 27474	11/13/2013	2920306	09/23/2015	502018000 027474	06/27/2018	Abandoned
C0005JP001	Japan	Delivery of therapeutic agent	2015-542258	11/13/2013	2016-502404	01/28/2016	6391582	08/31/2018	Abandoned
C0005JP002	Japan	Delivery of therapeutic agent	2018-154386	11/13/2013	2020-114258	07/30/2020			Abandoned
C0005JP003	Japan	Delivery of therapeutic agent	2020-079915	04/30/2020					Abandoned
C0005LI001	Liechtenstein	Delivery of therapeutic agent	13789802.9	11/13/2013	2920306	09/23/2015	2920306	06/27/2018	Abandoned

48

Ref#	Country	Title	Application Number	Application Date	Publication Number	Publication Date	Patent Number	Grant Date	Status
C0005NL001	Netherlands	Delivery of therapeutic agent	13789802.9	11/13/2013	2920306	09/23/2015	2920306	06/27/2018	Abandoned
C0005WO001	PCT	Delivery of therapeutic agent	PCT/EP2013 /073740	11/13/2013	WO 2014/076137	05/22/2014			Expired ENT
C0009US001	United States	Therapeutic membrane vesicles	62/308,805	03/15/2016					Expired PAT
C0009US002	United States	Therapeutic membrane vesicles	16/084,169	03/15/2017	2020-0155703	05/21/2020			Abandoned
C0009AU001	Australia	Therapeutic membrane vesicles	2017232498	03/15/2017					Abandoned
C0009BR001	Brazil	Therapeutic membrane vesicles	BR11201806 87464	03/15/2017					Abandoned
C0009CA001	Canada	Therapeutic membrane vesicles	3,017,586	03/15/2017					Abandoned
C0009CN001	China P.R.	Therapeutic membrane vesicles	2017800177 85.5	03/15/2017					Abandoned
C0009EP001	EPC	Therapeutic membrane vesicles	17767451.2	03/15/2017	3430024	01/23/2019			Abandoned
С0009НК001	Hong Kong	Therapeutic membrane vesicles	19127000.8	03/15/2017	40003516A	04/09/2020			Abandoned
C0009IL001	Israel	Therapeutic membrane vesicles	261490	03/15/2017					Abandoned
C0009IN001	India	Therapeutic membrane vesicles	2018470376 77	03/15/2017	41/2018	10/12/2018			Abandoned
C0009JP001	Japan	Therapeutic membrane vesicles	2018-548834	03/15/2017					Abandoned
C0009KR001	Republic of Korea	Therapeutic membrane vesicles	10-2018- 7029763	03/15/2017	10-2018- 0122433	11/12/2018			Abandoned
C0009MX001	Mexico	Therapeutic membrane vesicles	MX/A/2018/ 011202	03/15/2017	MX/A/2018/011 202	03/28/2019			Abandoned

C0009SG002	C0009SG001	C0009RU001	C0009WO001	C0009NZ001	Ref#
Singapore	Singapore	Russian Federation	PCT	New Zealand	Country
Therapeutic membrane vesicles	Title				
1020200888 3S	1120180740 1R	2018136151	PCT/US2017 /022544	746672	Application Number
03/15/2017	03/15/2017	03/15/2017	03/15/2017	03/15/2017	Application Date
	11201807401R		WO 2017/161010		Publication Number
	09/27/2018		09/21/2017		Publication Date
					Patent Number
					Grant Date
Abandoned	Abandoned	Abandoned	Expired	Abandoned	Status

PATENT

REEL: 064251 FRAME: 0856

RECORDED: 07/11/2023